seekingalpha.com
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc.ETONNASDAQ
Loading
Latest News
Loading news...
zacks.com
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
globenewswire.com
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2025.
globenewswire.com
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
globenewswire.com
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas (“Pierre Fabre”). HEMANGEOL is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.
reuters.com
US FDA approves Eton Pharma's hormonal disorder drug
The U.S. Food and Drug Administration approved on Wednesday Eton Pharmaceuticals' oral liquid therapy for a rare childhood hormonal disorder, giving families an easier way to manage the condition and keep children hydrated.
globenewswire.com
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for DESMODA™ (desmopressin acetate) Oral Solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), as antidiuretic replacement therapy for patients of all ages.
globenewswire.com
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida.
globenewswire.com
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a product used to treat an ultra-rare condition that impacts fewer than 100 patients in the United States.
seekingalpha.com
Eton Pharmaceuticals: An Undervalued Small Cap With High Growth
Eton offers a diversified, acquisition-driven portfolio in ultra-rare pediatric endocrinology and metabolic diseases, targeting significant peak sales potential. My DCF-based Fair Value is $28.1, representing 85% upside; optimistic scenarios suggest up to $40 per share, while downside risk is mitigated by product diversification. Revenue growth, free cash flow positivity, and declining SG&A margins support a Buy-to-Strong Buy stance at $15.17, despite high uncertainty from US drug pricing.
globenewswire.com
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team, will host a fireside chat at the Piper Sandler 37th Annual Healthcare Conference being held in NYC as follows: DATE: Thursday, December 4, 2025 TIME: 9:30AM ETLOCATION: Lotte New York Palace To schedule a 1x1 meeting with the Company, please contact your Piper Sandler institutional sales representative.
defenseworld.net
Acadian Asset Management LLC Sells 9,713 Shares of Eton Pharmaceuticals, Inc. $ETON
Acadian Asset Management LLC decreased its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 2.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 392,715 shares of the company's stock after selling 9,713 shares during the quarter. Acadian Asset Management
globenewswire.com
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference being held November 18, 2025 in New York, NY.
seekingalpha.com
Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. ( ETON ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - President, CEO & Director James Gruber - CFO, Treasurer & Secretary Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division Swayampakula Ramakanth - H.C.
zacks.com
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.02 per share a year ago.
globenewswire.com
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growth Q3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 million ET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026 GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patients Held positive FDA meeting clarifying pathway to KHINDIVI™ label expansion Submitted proposed clinical study to support INCRELEX® label expansion Generated $12.0 million of cash from operations in the quarter Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2025.
globenewswire.com
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025.
globenewswire.com
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA.
seekingalpha.com
Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.
seekingalpha.com
Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options
Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to fair value ($26.17) in the base case, with even higher potential in optimistic scenarios. Risks include pipeline failures and US drug price pressures, but even pessimistic scenarios suggest current valuation is fair, limiting downside.